Details werden geladen...
At ASCO, positive data for Bristol in multiple myeloma and Pfizer in lung cancer
You’re reading the web edition of ASCO in 30 Seconds, STAT’s guide to the American Society of Clinical Oncology annual meeting. Sign up for email editions
Ähnliche Seiten
An ASCO preview: What to watch for at cancer research's big meeting | STAT
https://www.statnews.com/2026/05/28/asco-preview-cancer-meeting/BioNTech and Pfizer tout bispecifics data, and Pazdur sees silver lining at FDA
https://www.statnews.com/2026/05/30/asco-news-day-2-biontech-pfizer-kelun-merck-pazdur/
HUTCHMED Highlights Clinical Data to be Presented at the 2026 ASCO Annual Meeting | The Manila Times
https://www.manilatimes.net/2026/05/22/tmt-newswire/globenewswire/hutchmed-highlights-clinical-data-to-be-presented-at-the-2026-asco-annual-meeting/2349755
Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer
https://www.finanznachrichten.de/nachrichten-2026-05/68638430-immatics-presents-data-on-ima401-magea4-8-bispecific-at-2026-asco-annual-meeting-with-simultaneous-publication-in-nature-medicine-supporting-developme-399.htmKelun-Biotech Presents Pivotal Phase II Data for Lunbotinib Fumarate (A400/EP0031) in RET Fusion-Positive NSCLC at 2026 ASCO | The Manila Times
https://www.manilatimes.net/2026/05/30/tmt-newswire/pr-newswire/kelun-biotech-presents-pivotal-phase-ii-data-for-lunbotinib-fumarate-a400ep0031-in-ret-fusion-positive-nsclc-at-2026-asco/2355013